Primaquine 30 mg/day versus 15 mg/day during 14 days for the prevention of Plasmodium vivax relapses in adults in French Guiana: a historical comparison

MLA

Epelboin, Loïc, et al. “Primaquine 30 Mg/Day versus 15 Mg/Day during 14 Days for the Prevention of Plasmodium Vivax Relapses in Adults in French Guiana: A Historical Comparison.” Malaria Journal, vol. 17, June 2018. EBSCOhost, https://doi.org/10.1186/s12936-018-2378-2.

APA

Epelboin, L., Caumes, E., Guermonprez, G., Leturcq, F., Clarke, P., Nacher, M., Adenis, A., Huber, F., Hallet, E., Abboud, P., Mosnier, E., Bideau, B., Marty, C., Lucarelli, A., Morel, V., Lacapère, F., Couppié, P., Paraskevis, D., Valdes, A., … Djossou, F. (2018). Primaquine 30 mg/day versus 15 mg/day during 14 days for the prevention of Plasmodium vivax relapses in adults in French Guiana: a historical comparison. Malaria Journal, 17. https://doi.org/10.1186/s12936-018-2378-2

Chicago

Epelboin, Loïc, Eric Caumes, Geraldine Guermonprez, France Leturcq, Peter Clarke, Mathieu Nacher, Antoine Adenis, et al. 2018. “Primaquine 30 Mg/Day versus 15 Mg/Day during 14 Days for the Prevention of Plasmodium Vivax Relapses in Adults in French Guiana: A Historical Comparison.” Malaria Journal 17 (June). doi:10.1186/s12936-018-2378-2.